Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease

Christoph Weigel; Haley Klimaszewski; Fode Tounkara; Selamawit Addissie; Sarah Schlotter; Betsy Pray; James P. Dugan; Bradley M. Haverkos; Lynda Villagomez; Mark Lustberg; Pierluigi Porcu; Timothy Voorhees; Richard F. Ambinder; Shannon C. Kenney; Joyce Fingeroth; Henri‐Jacques Delecluse; Michael A. Caligiuri; Lapo Alinari; Ginny L. Bumgardner; Christopher C. Oakes; Robert A. Baiocchi

doi:10.1016/j.bneo.2026.100200

Abstract

This is the authors' abstract. We don't add key points for this paper.

Key Points • Methylation loss and increased expression of EBV BGLF4 was associated with favorable response to the GARD regimen in aggressive EBV-CNSL.• Epigenetic regulation of lytic BGLF4 expression in a latent EBV malignancy supports EBV DNA methylation as a clinically relevant biomarker.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Weigel et al. (2026) studied this question.

synapsesocial.com/papers/6a8c2ad029efb9ec64c46a2b https://doi.org/10.1016/j.bneo.2026.100200

View Full Paper

Ask AI

Bookmark

Share

Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease

Abstract

Ask about this paper

Discussion

Cite This Study

Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading